EUVIMEDEUVIMED entdecken
Crossref

Prevention and treatment of type 1 diabetes: in search of the ideal combination therapy targeting multiple immunometabolic pathways

Marcelo Maia Pinheiro, Felipe Moura Maia Pinheiro, Maria Luisa Garo, Donatella Pastore, Francesca Pacifici, Camillo Ricordi, David Della-Morte, Marco Infante

Metabolism and Target Organ Damage · 16.05.2024 · 4 (3)

DOI: 10.20517/mtod.2024.12 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Metabolism and Target Organ Damage, online erschienen am 16.05.2024. Verfasst von Marcelo Maia Pinheiro und 7 weiteren Autor:innen. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 80 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Type 1 diabetes (T1D) represents an autoimmune disease caused by the gradual immune-mediated destruction of the insulin-producing beta cells within the pancreatic islets of Langerhans, resulting in the lifelong need for exogenous insulin therapy. According to recent estimates, T1D currently affects about 8.4 million individuals worldwide. Since a definitive biological cure for this disease is not available yet, there is a great need for novel therapeutic strategies aimed at safely and effectively altering the natural history of the disease during its sequential stages. Ideal therapeutic goals in T1D include the prevention of autoimmune beta-cell destruction, the preservation of residual beta-cell mass and endogenous insulin secretion, the replacement and/or regeneration of beta cells, as well as automated insulin delivery through advanced closed-loop artificial pancreas systems. With this regard, an important research area focused on the identification of a definitive biological cure for T1D is represented by the investigation of immunotherapeutic and beta-cell-protective agents used as disease-modifying therapies to forestall or eliminate insulin dependence. In this commentary, we discuss the reasons why the use of combination therapies targeting the multiple immunometabolic dysfunctions associated with T1D (other than beta-cell autoimmunity) is likely to be more effective in preserving beta cell function in individuals at different stages of T1D, as compared to the use of single therapeutic agents.

Zitieren

APA

Pinheiro, M. M., Pinheiro, F. M. M., Garo, M. L., Pastore, D., Pacifici, F., Ricordi, C., Della-Morte, D., & Infante, M. (2024). Prevention and treatment of type 1 diabetes: in search of the ideal combination therapy targeting multiple immunometabolic pathways. Metabolism and Target Organ Damage, 4(3). https://doi.org/10.20517/mtod.2024.12

Vancouver

Pinheiro MM, Pinheiro FMM, Garo ML, Pastore D, Pacifici F, Ricordi C, et al. Prevention and treatment of type 1 diabetes: in search of the ideal combination therapy targeting multiple immunometabolic pathways. Metabolism and Target Organ Damage. 2024;4(3). doi:10.20517/mtod.2024.12

BibTeX
@article{Pinheiro2024,
  author = {Pinheiro, Marcelo Maia and Pinheiro, Felipe Moura Maia and Garo, Maria Luisa and Pastore, Donatella and Pacifici, Francesca and Ricordi, Camillo and Della-Morte, David and Infante, Marco},
  title = {Prevention and treatment of type 1 diabetes: in search of the ideal combination therapy targeting multiple immunometabolic pathways},
  journal = {Metabolism and Target Organ Damage},
  year = {2024},
  volume = {4},
  number = {3},
  doi = {10.20517/mtod.2024.12}
}
Kostenlos starten →